

Amphastar Pharmaceuticals, Inc.
 Form 4/A
 February 03, 2016

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Zhang Jack Y.

2. Issuer Name and Ticker or Trading Symbol
 Amphastar Pharmaceuticals, Inc.
 [AMPH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 06/10/2015

Director 10% Owner
 Officer (give title below) Other (specify below)
 CEO & Chief Science Officer

C/O AMPHASTAR
 PHARMACEUTICALS,
 INC., 11570 6TH STREET
 (Street)

4. If Amendment, Date Original Filed(Month/Day/Year)
 06/12/2015

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

RANCHO
 CUCAMONGA, CA 91730
 (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Stock	06/10/2015		M		12,975 A \$ 12.97	935,112	D
Common Stock	06/10/2015		S ⁽¹⁾		11,731 D \$ 16.3792	923,381	D
Common Stock	06/11/2015		M		12,860 A \$ 12.97	936,241	D
Common Stock	06/11/2015		S ⁽¹⁾		11,600 D \$ 16.4694	924,641	D

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4/A

				<u>(3)</u>				
Common Stock	06/12/2015	M	83,253	A	\$ 12.97	1,007,894	D	
Common Stock	06/12/2015	<u>S(1)</u>	75,618	D	\$ <u>(4)</u>	16.1487 932,276	D	
Common Stock	06/10/2015	M	12,619	A	\$ 12.97	686,143	I	See footnote <u>(5)</u>
Common Stock	06/10/2015	<u>S(1)</u>	11,411	D	\$ <u>(6)</u>	16.3719 674,732	I	See footnote <u>(5)</u>
Common Stock	06/11/2015	M	12,930	A	\$ 12.97	687,662	I	See footnote <u>(5)</u>
Common Stock	06/11/2015	<u>S(1)</u>	11,664	D	\$ <u>(7)</u>	16.4689 675,998	I	See footnote <u>(5)</u>
Common Stock	06/12/2015	M	42,223	A	\$ 12.97	718,221	I	See footnote <u>(5)</u>
Common Stock	06/12/2015	<u>S(1)</u>	38,471	D	\$ <u>(8)</u>	16.1673 679,750	I	See footnote <u>(5)</u>
Common Stock						7,631,594	I	See footnote <u>(9)</u>
Common Stock						5,000	I	See footnote <u>(10)</u>
Common Stock						200,000	I	See footnote <u>(11)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction	5. Number of Derivative	6. Date Exercisable and Expiration Date	7. Title and Amount of Underlying Securities
------------------------	---------------	--------------------------------------	-------------------------------	----------------	-------------------------	-----------------------------------------	----------------------------------------------

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4/A

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)	
					Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 12.97	06/10/2015	M	12,975	(12)	09/28/2015	Common Stock	12,975
Employee Stock Option (right to buy)	\$ 12.97	06/11/2015	M	12,860	(12)	09/28/2015	Common Stock	12,860
Employee Stock Option (right to buy)	\$ 12.97	06/12/2015	M	83,253	(12)	09/28/2015	Common Stock	83,253
Employee Stock Option (right to buy)	\$ 12.97	06/10/2015	M	12,619	(12)	09/28/2015	Common Stock	12,619
Employee Stock Option (right to buy)	\$ 12.97	06/11/2015	M	12,930	(12)	09/28/2015	Common Stock	12,930
Employee Stock Option (right to buy)	\$ 12.97	06/12/2015	M	42,223	(12)	09/28/2015	Common Stock	42,223

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Zhang Jack Y. C/O AMPHASTAR PHARMACEUTICALS, INC.	X	X	CEO & Chief Science Officer	

11570 6TH STREET
RANCHO CUCAMONGA, CA 91730

Luo Mary Z.
C/O AMPHASTAR PHARMACEUTICALS, INC. X X COO, Chief Scientist, Chairman
11570 6TH STREET
RANCHO CUCAMONGA, CA 91730

Signatures

/s/ Ken Stupak, by power of attorney for Jack Y. Zhang 02/03/2016

__Signature of Reporting Person Date

/s/ Ken Stupak, by power of attorney for Mary Z. Luo 02/03/2016

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the each of the reporting persons on December 16, 2014.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.25 to \$16.61, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6), (7) and (8) to this Form 4.
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.38 to \$16.62, inclusive.
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.02 to \$16.49, inclusive.
- (5) The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
- (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.24 to \$16.55, inclusive.
- (7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.37 to \$16.61, inclusive.
- (8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.03 to \$16.39, inclusive.
- (9) The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons are the sole owners.
- (10) The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
- (11) The shares are held of record by a trust for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
- (12) Shares subject to the option are fully vested and immediately exercisable.

Remarks:

This amended and restated Form 4 (the "Form 4/A") is filed to update the previously filed Form 4 which reported withholding
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.